性能参数 |
|||
产品名称 |
Carfilzomib |
||
规格 |
10mM (in 1mL DMSO) 5mg 10mg 25mg |
||
货号 |
GOY-Y2237 |
||
含量 |
>98.00% |
||
CAS |
868540-17-4 |
||
别名 |
PR 171,PR171,PR-171,Carfilzomib |
|
|
化学名 |
(2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide |
分子式 |
C40H57N5O7 |
分子量 |
分子 719.91 |
溶解度 |
≥ 36.0mg/mL in DMSO |
储存条件 |
Desiccate at -20°C |
General tips |
|
用途 |
仅供科研 |
价格 |
电询 |
|
|||
详细内容 |
Carfilzomib displays preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, with over 80% inhibition at doses of 10 nM and above and little or no effect on the PGPH and T-L activities at doses up to 100 nM. Carfilzomib decreases the viability of ANBL-6, RPMI 8226 cells, U266 and KAS-6/1 cells with an IC50 less than 5 nM. Carfilzomib overcome Dex resistance, in that MM1.R cells reveals an IC50 of 15.2 nM, less than the value of 29.3 nM for parental MM1.S cells[1]. Co-treatment with carfilzomib and HDACIs leads to synergistic induction of cell death in various mantle cell lymphoma lines and primary mantle cell lymphoma cells. Combined treatment with carfilzomib or ONX0912 with vorinostat in HF-4B and Granta cells sharply increases caspase activation, PARP cleavage, JNK activation, MnSOD2 induction, and DNA damage[2]. Carfilzomib (2.0 mg/kg, i.v.) in conbination with 70 mg/kg vorinostat virtually abrogates tumor growth in Granta-luciferace cell xenograft flank model. Combined treatment results in a pronounced reduction in bioluminescence compared to animals treated with single agents or controls with minimal toxicity[2]. References: [1]. Kuhn DJ, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90. [2]. Dasmahapatra G, et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2011 Sep;10(9):1686-97. |
公司正在销售的产品:
2,2'-二硫双(5-硝基吡啶) 97% 丰度:99atom%;化学纯度:≥98.5% 3,3'-二硫代二丙酸 99% 丰度:10atom%;化学纯度:≥98.5% 双戊烯 95% 丰度:99atom%;化学纯度:≥99.9,氖20和氖22以47:53比例混合 邻苯二甲酸二异丙酯 98% 丰度:10atom%;化学纯度:≥98% 2,5-二乙氧基苯胺 97% 丰度:99atom%;化学纯度:≥98% 2,5-二甲基苯基溴化镁 1M THF溶液 丰度:10atom%;化学纯度:≥98% |
FAK inhibitor 2100mg 250mg 500mg>98.00%Cas No. N/AC29H33F3N8O2S2 FAK Inhibitor 1410mM (in 1mL Water) 10mg 50mg>98.00%Cas No. 4506-66-5C6H10N4.4HCl F-1100mg 250mg 500mg>98.00%Cas No. 2244775-31-1C22H27ClN8O3S Erlotinib Hydrochloride10mM (in 1mL DMSO) 1g 5g>98.00%Cas No. 183319-69-9C22H24ClN3O4 Erlotinib10mM (in 1mL DMSO) 1g 5g>98.00%Cas No. 183321-74-6C22H23N3O4 FLT3-IN-6100mg 250mg 500mg>98.00%Cas No. N/AC23H25N5O3 FLT3-IN-4100mg 250mg 500mg>98.00%Cas No. 2304799-09-3C23H25N7O2 |
传真号码:021-39596320 021-39921927
QQ: 3004918891 3004905818 3004901493
移动电话:18321818584 15026555973
地址:上海松江新砖公路1155号
产品均为实验试剂,仅供科研实验使用,非药品、非食品、不可用于动物及人体!